Research and development of novel antimicrobials urgently needed
Leqembi’s benefits outweigh risks in a restricted patient population
A new tool to respond rapidly to emerging animal and public health threats
CHMP recommends eight new medicines for approval in the EU
Send us your comments by 30 November 2024
How to improve quality of marketing authorisation application submissions
Find medicine
What's new
FAQs
Latest news
Use of opioid medicines with Mysimba may lead to serious side effects
Leqembi (lecanemab) recommended for treatment of early Alzheimer’s disease
Re-examination concludes that benefits outweigh risks in a restricted patient population
Platform technologies enable rapid response to emerging infectious disease threats
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
PRAC carried out its broad range of responsibilities for managing the risks associated with medicine use
Information for you
Patients and carers
Healthcare professionals
Animal health professionals
Pharmaceutical Industry
Media
